Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts.

Autor:	Eng PC; Department of Metabolism, Digestion and Reproduction, Imperial College London, UK.; Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust, London, UK., Forlano R; Department of Metabolism, Digestion and Reproduction, Imperial College London, UK.; Department of Hepatology, Imperial College Healthcare NHS Trust, London, UK., Tan T; Department of Metabolism, Digestion and Reproduction, Imperial College London, UK.; Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust, London, UK., Manousou P; Department of Metabolism, Digestion and Reproduction, Imperial College London, UK.; Department of Hepatology, Imperial College Healthcare NHS Trust, London, UK., Dhillo WS; Department of Metabolism, Digestion and Reproduction, Imperial College London, UK.; Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust, London, UK., Izzi-Engbeaya C; Department of Metabolism, Digestion and Reproduction, Imperial College London, UK.; Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Jazyk:	angličtina
Zdroj:	JHEP reports : innovation in hepatology [JHEP Rep] 2023 Jun 29; Vol. 5 (10), pp. 100835. Date of Electronic Publication: 2023 Jun 29 (Print Publication: 2023).
DOI:	10.1016/j.jhepr.2023.100835
Abstrakt:	Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide, affecting up to 30% of adults. Progression to non-alcoholic steatohepatitis (NASH) is a key risk factor for cirrhosis, hepatocellular carcinoma and cardiovascular events. Alterations in reproductive hormones are linked to the development and/or progression of NAFLD/NASH in women. Women with polycystic ovary syndrome and those with oestrogen deficiency are at increased risk of NAFLD/NASH, with higher mortality rates in older women compared to men of similar ages. NAFLD/NASH is currently the leading indication for liver transplantation in women without hepatocellular carcinoma. Therefore, a better understanding of NAFLD in women is needed to improve outcomes. In this review, we discuss the hormonal and non-hormonal factors that contribute to NAFLD development and progression in women. Furthermore, we highlight areas of focus for clinical practice and for future research. Competing Interests: All authors report no potential conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu